ghrelin
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer, Cachexia
Trial Timeline
Jun 1, 2009 → Dec 1, 2011
NCT ID
NCT00933361About ghrelin
ghrelin is a phase 1/2 stage product being developed by Bachem for Advanced Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00933361. Target conditions include Advanced Cancer, Cachexia.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00933361 | Phase 1/2 | Completed |
Competing Products
20 competing products in Advanced Cancer